ArticlePloS one2014
Isolation and characterization of an agaro-oligosaccharide (AO)-hydrolyzing bacterium from the gut microflora of Chinese individuals.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 94 citations in OpenAlex.
- Depolymerized Fucoidan Alleviates High-Fat Diet-Induced Obesity in Association with Alterations in Gut Microbiota and Metabolic Profiles.Foods (Basel, Switzerland) · 2026Article
- Butyrate Produced by Gut Microbiota Regulates Atherosclerosis: A Narrative Review of the Latest Findings.International journal of molecular sciences · 2025Review
- New connections of medication use and polypharmacy with the gut microbiota composition and functional potential in a large population.Scientific reports · 2024Article
- Gelatine Blends Modified with Polysaccharides: A Potential Alternative to Non-Degradable Plastics.International journal of molecular sciences · 2024Article
- Evaluation of Intestinal Microbial Metabolites in Preterm Infants with Different Initial Feeding Methods by In Vitro Fermentation Modeling System.Microorganisms · 2022Article
- Characterization of a Thermostable Lichenase fromJournal of microbiology and biotechnology · 2022Article
- Multi-Step Enzymatic Production and Purification of 2-Keto-3-Deoxy-Galactonate from Red-Macroalgae-Derived Agarose.Marine drugs · 2022Article
- Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice.Journal of genetics and genomics = Yi chuan xue bao · 2021Article
- Metabolic and enzymatic elucidation of cooperative degradation of red seaweed agarose by two human gut bacteria.Scientific reports · 2021Article
- Characterization of Neoagarooligosaccharide HydrolaseMarine drugs · 2021Article
- Age-related changes of microbiota in midlife associated with reduced saccharolytic potential: an in vitro study.BMC microbiology · 2021Article
- Mechanisms Linking the Gut-Muscle Axis With Muscle Protein Metabolism and Anabolic Resistance: Implications for Older Adults at Risk of Sarcopenia.Frontiers in physiology · 2021Review
- The Pros and Cons of Using Algal Polysaccharides as Prebiotics.Frontiers in nutrition · 2020Review
- Prebiotics from Seaweeds: An Ocean of Opportunity?Marine drugs · 2019Review
- Evaluation of Prebiotic Potential of Three Marine Algae Oligosaccharides from Enzymatic Hydrolysis.Marine drugs · 2019Article
- Salivary and Gut Microbiomes Play a Significant Role in in Vitro Oral Bioaccessibility, Biotransformation, and Intestinal Absorption of Arsenic from Food.Environmental science & technology · 2018Article
- Oligosaccharides Derived from Red Seaweed: Production, Properties, and Potential Health and Cosmetic Applications.Molecules (Basel, Switzerland) · 2018Review
- Probiotics in human gut microbiota can degrade host glycosaminoglycans.Scientific reports · 2018Article
- Quantification of Neoagaro-Oligosaccharide Production through Enzymatic Hydrolysis and Its Anti-Oxidant Activities.Molecules (Basel, Switzerland) · 2018Article
- Molecular basis of an agarose metabolic pathway acquired by a human intestinal symbiont.Nature communications · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Agarose (AP) from red algae has a long history as food ingredients in East Asia. Agaro-oligosaccharides (AO) derived from AP have shown potential prebiotic effects. However, the human gut microbes responsible for the degradation of AO and AP have not yet been fully investigated. Here, we reported that AO and AP can be degraded and utilized at various rates by fecal microbiota obtained from different individuals. Bacteroides uniformis L8 isolated from human feces showed a pronounced ability to degrade AO and generate D-galactose as its final end product. PCR-DGGE analysis showed B. uniformis to be common in the fecal samples, but only B. uniformis L8 had the ability to degrade AO. A synergistic strain, here classified as Escherichia coli B2, was also identified because it could utilize the D-galactose as the growth substrate. The cross-feeding interaction between B. uniformis L8 and E. coli B2 led to exhaustion of the AO supply. Bifidobacterium infantis and Bifidobacterium adolescentis can utilize one of the intermediates of AO hydrolysis, agarotriose. Growth curves indicated that AO was the substrate that most favorably sustained the growth of B. uniformis L8. In contrast, κ-carrageenan oligosaccharides (KCO), guluronic acid oligosaccharides (GO), and mannuronic acid oligosaccharides (MO) were found to be unusable to B. uniformis L8. Current results indicate that B. uniformis L8 is a special degrader of AO in the gut microbiota. Because B. uniformis can mitigate high-fat-diet-induced metabolic disorders, further study is required to determine the potential applications of AO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.